Truist Financial
LXRX icon

Truist Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

Truist Financial’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.6K Hold
14,000
– – ﹤0.01% 2896
2026
Q1 		$21.8K Hold
14,000
– – ﹤0.01% 2773
2025
Q4 		$16.1K Hold
14,000
– – ﹤0.01% 2751
2025
Q3 		$18.9K Hold
14,000
– – ﹤0.01% 2702
2025
Q2 		$13.2K Hold
14,000
– – ﹤0.01% 2583
2025
Q1 		$6.45K Hold
14,000
– – ﹤0.01% 2539
2024
Q4 		$10.3K Buy
14,000
+600
+4% +$723 ﹤0.01% 2504
2024
Q3 		$21K Hold
13,400
– – ﹤0.01% 2470
2024
Q2 		$22.5K Buy
13,400
+400
+3% +$718 ﹤0.01% 2620
2024
Q1 		$31.2K Buy
13,000
+500
+4% +$1.07K ﹤0.01% 2593
2023
Q4 		$19.1K Buy
12,500
+500
+4% +$595 ﹤0.01% 2616
2023
Q3 		$13.1K Buy
+12,000
New +$21.1K ﹤0.01% 2569

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Truist Financial's LXRX Position: Q2 2026 in Review

Truist Financial held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 14,000 shares worth $33.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

Truist Financial first reported a position in LXRX in Q3 2023 and has held it in 12 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Truist Financial held 14,000 shares of Lexicon Pharmaceuticals worth $33.6K as of Q2 2026.
  • Truist Financial left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2896 holding.
  • Truist Financial first reported a position in Lexicon Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.